Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2026)

Ovid Therapeutics filings provide 6 years of Long-Term Investments readings, the most recent being $10.1 million for Q1 2026.

  • Quarterly Long-Term Investments fell 51.81% to $10.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Mar 2026, down 51.81% year-over-year, with the annual reading at $42.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments hit $10.1 million in Q1 2026 for Ovid Therapeutics, down from $42.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $42.0 million in Q4 2025 and bottomed at $2.2 million in Q2 2022.
  • Average Long-Term Investments over 5 years is $15.7 million, with a median of $17.0 million recorded in 2023.
  • The largest annual shift saw Long-Term Investments surged 639.07% in 2023 before it plummeted 51.81% in 2026.
  • Ovid Therapeutics' Long-Term Investments stood at $5.6 million in 2022, then surged by 213.49% to $17.6 million in 2023, then increased by 19.85% to $21.1 million in 2024, then surged by 98.63% to $42.0 million in 2025, then plummeted by 75.99% to $10.1 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Long-Term Investments are $10.1 million (Q1 2026), $42.0 million (Q4 2025), and $20.9 million (Q3 2025).